NT_1170x120_1-11-18

Genentech

PhRMA welcomes Genentech and Gilead Sciences to association

PhRMA welcomes Genentech and Gilead Sciences to association

WASHINGTON – Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Genentech, a member of the Roche Group, South San Francisco, and Gilead Sciences, Inc., Foster City, Calif. joined the association as members. Genentech and Gilead Sciences are two of the world’s leading biopharmaceutical companies dedicated to discovering and developing medicines to fundamentally change how patients with life-threatening

Genentech announces FDA approval of Xofluza (baloxavir marboxil) for influenza

Genentech announces FDA approval of Xofluza (baloxavir marboxil) for influenza

SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the Roche Group  announced that the U.S. Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. Xofluza is a first-in-class, single-dose oral medicine with a novel proposed mechanism of action

Soleo Health selected by Genentech to provide two limited distribution drugs

Soleo Health selected by Genentech to provide two limited distribution drugs

McKINNEY, Texas — Soleo Health, an innovative leader in specialty infusion services, announced the company has been selected by Genentech (member of the Roche Group), a world-leading biotechnology company with multiple products on the market and a strong development pipeline, to dispense two limited distribution drugs, Hemlibra and Ocrevus. Hemlibra (emicizumab-kxwh), for patients with hemophilia A with factor VIII inhibitors, received approval from

FDA grants priority review to single-dose flu drug

FDA grants priority review to single-dose flu drug

SOUTH SAN FRANCISCO, Calif. — Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in people 12 years and older. The FDA is expected to make a decision on approval by

Mylan gains FDA approval for Herceptin biosimilar

Mylan gains FDA approval for Herceptin biosimilar

PITTSBURGH and BENGALURU, India — Mylan N.V. has received Food and Drug Administration approval for Ogivri (trastuzumab-dkst), a biosimilar oncology drug co-developed with Biocon Ltd. Mylan said Friday that Ogivri is a biosimilar of Herceptin (trastuzumab) from Genentech, indicated for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

HDA names executive committee, research board members

HDA names executive committee, research board members

ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) has made new appointments to its executive committee and HDA Research Foundation board of directors. HDA said Thursday that Paul Dickson, president of Morris & Dickson Co., has been elected as a member of the HDA Executive Committee. He currently serves as a member of the HDA

H.D. Smith Jr. honored with Nexus Award

H.D. Smith Jr. honored with Nexus Award

COLORADO SPRINGS, Colo. — Henry Dale Smith Jr., chairman and chief executive officer of H.D. Smith Holding Co., has received the 2016 Nexus Award for Lifetime Achievement from the HDA Research Foundation. Smith was presented the award, the pharmaceutical distribution industry’s highest individual honor, at the Healthcare Distribution Alliance (HDA) 2016 Business and Leadership Conference